阳性NSCLC-话题@MedSci - williamhill asia

#阳性NSCLC#

36篇内容 | 920人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1816366, encodeId=660d1816366c6, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, objectType=article, longId=729047, objectId=d22fe2904783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22fe2904783, replyNumber=0, likeNumber=83, createdTime=2022-10-25, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22fe2904783, moduleTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d22fe2904783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816364, encodeId=25421816364fc, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=87, createdTime=2022-09-26, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816365, encodeId=972a18163652f, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, objectType=article, longId=727300, objectId=7f29e2730032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f29e2730032, replyNumber=0, likeNumber=62, createdTime=2022-06-19, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f29e2730032, moduleTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7f29e2730032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816363, encodeId=7bb7181636373, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=82, createdTime=2022-04-12, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816361, encodeId=f044181636104, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, objectType=article, longId=221572, objectId=bfd12215e24f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfd12215e24f, replyNumber=0, likeNumber=68, createdTime=2022-02-04, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfd12215e24f, moduleTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bfd12215e24f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816362, encodeId=440d1816362bc, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=53, createdTime=2022-05-28, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816360, encodeId=18ac18163607f, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者, objectType=article, longId=221110, objectId=ba8922111014, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba8922111014, replyNumber=0, likeNumber=85, createdTime=2022-02-12, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba8922111014, moduleTitle=APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ba8922111014)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816356, encodeId=356e18163561a, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, objectType=article, longId=220083, objectId=ae6a2200837d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6a2200837d, replyNumber=0, likeNumber=53, createdTime=2022-07-27, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6a2200837d, moduleTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ae6a2200837d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816359, encodeId=94671816359dc, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=220889, objectId=d4ae2208892d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ae2208892d, replyNumber=0, likeNumber=141, createdTime=2022-07-16, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ae2208892d, moduleTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d4ae2208892d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816352, encodeId=7e96181635232, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, objectType=article, longId=207818, objectId=f15320e81875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15320e81875, replyNumber=0, likeNumber=53, createdTime=2021-05-27, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15320e81875, moduleTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f15320e81875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816357, encodeId=5d5e181635eb2, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, objectType=article, longId=220334, objectId=0e9e2203349a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e9e2203349a, replyNumber=0, likeNumber=70, createdTime=2022-04-13, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e9e2203349a, moduleTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0e9e2203349a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816358, encodeId=9386181635881, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, objectType=article, longId=220696, objectId=2d11220696ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d11220696ee, replyNumber=0, likeNumber=0, createdTime=2022-05-15, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d11220696ee, moduleTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2d11220696ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816351, encodeId=9f931816351b8, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, objectType=article, longId=207814, objectId=aa0620e814a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa0620e814a1, replyNumber=0, likeNumber=71, createdTime=2021-12-15, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa0620e814a1, moduleTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=aa0620e814a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816355, encodeId=0360181635501, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , objectType=article, longId=217043, objectId=644421e04318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644421e04318, replyNumber=0, likeNumber=0, createdTime=2022-08-13, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644421e04318, moduleTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=644421e04318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816354, encodeId=076a18163541d, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), objectType=article, longId=215428, objectId=756f215428da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f215428da, replyNumber=0, likeNumber=65, createdTime=2021-12-17, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f215428da, moduleTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=756f215428da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816353, encodeId=6cb61816353d6, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=59, createdTime=2021-10-07, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816350, encodeId=1f3c181635053, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, objectType=article, longId=200981, objectId=96e62009817d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96e62009817d, replyNumber=0, likeNumber=69, createdTime=2020-10-04, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96e62009817d, moduleTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=96e62009817d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816349, encodeId=875e1816349ca, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, objectType=article, longId=198887, objectId=e4c319888efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c319888efe, replyNumber=0, likeNumber=62, createdTime=2021-01-07, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c319888efe, moduleTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e4c319888efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816348, encodeId=8bf8181634849, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择, objectType=article, longId=191175, objectId=f0141911e5a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0141911e5a2, replyNumber=0, likeNumber=65, createdTime=2020-05-20, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0141911e5a2, moduleTitle=褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f0141911e5a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1816345, encodeId=17c7181634589, content=<a href='/topic/show?id=28dd9e5029b' target=_blank style='color:#2F92EE;'>#阳性NSCLC#</a>, objectTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=58, createdTime=2019-08-31, rootId=0, userName=ms7258648636991762, userId=03202500144, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

阳性NSCLC

2020-05-29

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！

2022-10-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-09-26

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC

2022-06-19

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-04-12

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效

2022-02-04

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-05-28

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者

2022-02-12

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗

2022-07-27

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效

2022-07-16

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%

2021-05-27

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性

2022-04-13

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

A+T在EGFR突变阳性NSCLC的治疗新格局

2022-05-15

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效

2021-12-15

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效

2022-08-13

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究)

2021-12-17

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2021-10-07

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益

2020-10-04

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期

2021-01-07

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

褚倩教授：EGFR 19del和21L858R突变阳性NSCLC的差异与治疗选择

2020-05-20

ms7258648636991762 (审核中...)

前往app查看评论内容

#阳性NSCLC#

罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC

2019-08-31

科室
- - 订阅+
  - 更多科室
工具
服务